364 research outputs found
GEOGRAFIE DEL VINO: COSTRUZIONE STORICA E PATRIMONIALIZZAZIONE DEI PAESAGGI VITICOLI
This research project is supposed to face up viticulture in a complex, epistemological framework. As Dickenson and Salt affirm the geography of the wine \uabmay be studied from a variety of perspectives and encompasses the influence of the physical environment, historical diffusion of the vine and viticulture, economic geographies of cultivation and marketing, political influences on trade and production, and cultural perceptions of landscapes, product and people\ubb. After all, already in the Latin etymology of viticulture exists a deep content hiatus that imposes to consider two fair enough different concepts; indeed, culture may refer to cultivation and care. Therefore, it is crucial to understand how viticulture must be considered and to show the way its dichotomic nature may suggest distant methodologies of investigation.
After having underlined the epistemological framework of viticulture in relationship to geography and given the interpretative tools of the research, I analyzed the construction and the evolution of some viticultural landscapes (Montalcino, Barolo, Bolgheri and the C\uf4te d\u2019Or) whose choice depends on the dynamics that regarded their production (characterized by a particular propensity to commercialization), the relationships and the differences among them and finally the essential relationship that wine creates with its territory of origin. The role of the tradition represents the fil rouge that links these experiences and it declines in a different perspective according to the realities I analyzed. However, for each of them, it has been fundamental the role developed by a forerunner; indeed, Ferruccio Biondi for Brunello di Montalcino, Juliette Colbert-Falletti for Barolo and Mario Incisa della Rocchetta for the Sassicaia have not only contributed to the creation of a wine but generally to the development of a whole territory that is identified today in the cultivation of the grapevine.
Finally, in virtue of such a rooted and shared historical construction, these territories take part in the processes of patrimonialization that are characterizing some wine regions to a global scale. Following different criterions of classification, where however viticulture covers a preponderant aspect, Val d\u2019Orcia, Langhes and the climats de Bourgogne are considered from the UNESCO a human world heritage to safeguard while Bolgheri has been inserted by Regione Tuscana in the catalog of the historical rural landscapes; in all these cases, independently from who promoted the patrimonialization, the aim is clear: to allow the future generations to enjoy the cultural and environmental wealth that distinguish them. The wine landscapes are reported to be the ones that underwent fast and important transformations. Moving from this, I underline the debate around the relationship between patrimonialization (considered as a specific process of conservation) and the general transformation of the landscape. From this perspective, the criterions of patrimonialization adopted for the viticultural landscapes seem not to consider the eventuality of one change in the case wine shouldn\u2019t play the social and economic role that it has nowadays. What would it happen in that case
Gynecological surgical interventions (conservative and non-conservative): Clinical psychological variables and symptomatology pertaining to perioperative period
Objective: After considering great inter-individual variability of subjective experience and clinical
course in reference to conservative and non-conservative gynecological surgical interventions, an
attempt was made to evaluate potential role of several clinical and psychological variables with respect
to perioperative symptomatology course and illness behaviour.
Materials and methods: The sample consists of 58 women (mean age 41.4 ± 8.7) undergoing
gynecological surgical interventions (conservative and non-conservative ones) for benign pathologies.
The anamnestic and clinical data (psychological anamnesis, clinical history, indications, methods
and typology of the intervention) were collected using a specifically designed summary form. For
the evaluation of pre-and post-operative symptomatology course and illness behaviour, the following
psychological tests were respectively used: The Symptom Questionnaire (SQ), with 3 planned
administrations (respectively 15 days before the intervention, a day before the intervention and at
discharge) and the Illness Behavior Questionnaire (IBQ), completed before discharge. Non-parametric
tests (Mann-Whitney and Kruskal-Wallis) were used to compare performances on independent samples.
Results: Results show that perioperative course and illness behaviour in the cases of gynecological
surgical interventions for benign pathologies depend on clinical variables, that is, typology and methods
of the intervention, clinical history, psychopathological anamnesis.
Conclusion: Findings suggest the importance of clinical-anamnestic inquiry oriented towards the
evaluation of variables that emerged as risk factors, with the goal of planning personalized support
interventions for preventing and/or reducing distress and impact on psychophysical wellbeing arising
after gynaecological surgical interventions
A Declarative Framework for Specifying and Enforcing Purpose-aware Policies
Purpose is crucial for privacy protection as it makes users confident that
their personal data are processed as intended. Available proposals for the
specification and enforcement of purpose-aware policies are unsatisfactory for
their ambiguous semantics of purposes and/or lack of support to the run-time
enforcement of policies.
In this paper, we propose a declarative framework based on a first-order
temporal logic that allows us to give a precise semantics to purpose-aware
policies and to reuse algorithms for the design of a run-time monitor enforcing
purpose-aware policies. We also show the complexity of the generation and use
of the monitor which, to the best of our knowledge, is the first such a result
in literature on purpose-aware policies.Comment: Extended version of the paper accepted at the 11th International
Workshop on Security and Trust Management (STM 2015
Editorial: public health pharmacogenomics and the design principles for global public goods – moving genomics to responsible innovation
Evidence of an interaction between FXR1 and GSK3 beta polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics
Background:
Genome-Wide Association Studies (GWASs) have identified several genes associated with Schizophrenia (SCZ) and exponentially increased knowledge on the genetic basis of the disease. In addition, products of GWAS genes interact with neuronal factors coded by genes lacking association, such that this interaction may confer risk for specific phenotypes of this brain disorder. In this regard, fragile X mental retardation syndrome-related 1 (FXR1) gene has been GWAS associated with SCZ. FXR1 protein is regulated by glycogen synthase kinase-3β (GSK3β), which has been implicated in pathophysiology of SCZ and response to antipsychotics (APs). rs496250 and rs12630592, two eQTLs (Expression Quantitative Trait Loci) of FXR1 and GSK3β, respectively, interact on emotion stability and amygdala/prefrontal cortex activity during emotion processing. These two phenotypes are associated with Negative Symptoms (NSs) of SCZ suggesting that the interaction between these SNPs may also affect NS severity and responsiveness to medication.
Methods:
To test this hypothesis, in two independent samples of patients with SCZ, we investigated rs496250 by rs12630592 interaction on NS severity and response to APs. We also tested a putative link between APs administration and FXR1 expression, as already reported for GSK3β expression.
Results:
We found that rs496250 and rs12630592 interact on NS severity. We also found evidence suggesting interaction of these polymorphisms also on response to APs. This interaction was not present when looking at positive and general psychopathology scores. Furthermore, chronic olanzapine administration led to a reduction of FXR1 expression in mouse frontal cortex.
Discussion:
Our findings suggest that, like GSK3β, FXR1 is affected by APs while shedding new light on the role of the FXR1/GSK3β pathway for NSs of SCZ
Ventricular volume expansion in presymptomatic genetic frontotemporal dementia
Objective: To characterize the time course of ventricular volume expansion in genetic frontotemporal dementia (FTD) and identify the onset time and rates of ventricular expansion in presymptomatic FTD mutation carriers.
Methods: Participants included patients with a mutation in MAPT, PGRN, or C9orf72, or first-degree relatives of mutation carriers from the GENFI study with MRI scans at study baseline and at 1 year follow-up. Ventricular volumes were obtained from MRI scans using FreeSurfer, with manual editing of segmentation and comparison to fully automated segmentation to establish reliability. Linear mixed models were used to identify differences in ventricular volume and in expansion rates as a function of time to expected disease onset between presymptomatic carriers and noncarriers.
Results: A total of 123 participants met the inclusion criteria and were included in the analysis (18 symptomatic carriers, 46 presymptomatic mutation carriers, and 56 noncarriers). Ventricular volume differences were observed 4 years prior to symptom disease onset for presymptomatic carriers compared to noncarriers. Annualized rates of ventricular volume expansion were greater in presymptomatic carriers relative to noncarriers. Importantly, time-intensive manually edited and fully automated ventricular volume resulted in similar findings.
Conclusions: Ventricular volume differences are detectable in presymptomatic genetic FTD. Concordance of results from time-intensive manual editing and fully automatic segmentation approaches support its value as a measure of disease onset and progression in future studies in both presymptomatic and symptomatic genetic FTD
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.
IntroductionQuantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B-based and florbetapir-based amyloid imaging in the same participants from two independent cohorts using a crossover design.MethodsPittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter-individual variability of the two tracers were compared using multivariate linear models both cross-sectionally and longitudinally.ResultsGlobal amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers.DiscussionAlthough the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers
Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women
<p>Abstract</p> <p>Background</p> <p>As weight gain is one of the most frequently cited reasons for not using and for discontinuing hormonal contraceptives, in an open-label, single-arm, multicentre clinical study we evaluated the effect of the ethinylestradiol/norelgestromin contraceptive patch (EVRA, Janssen-Cilag International, Belgium) on body composition using bioelectrical impedance analysis (BIA).</p> <p>Methods</p> <p>Body weight and impedance vector components (resistance (R) and reactance (Xc), at 50 kHz frequency, Akern-RJL Systems analyzer) were recorded before entry, after 1, 3 and 6 months in 182 Italian healthy women aged 29 yr (18 to 45), and with BMI 21.8 kg/m<sup>2 </sup>(16 to 31). Total body water (TBW) was estimated with a BIA regression equation. Vector BIA was performed with the RXc mean graph method and the Hotelling's T<sup>2 </sup>test for paired and unpaired data.</p> <p>Results</p> <p>After 6 months body weight increased by 0.64 kg (1.1%) and TBW increased by 0.51 L (1.7%). The pattern of impedance vector displacement indicated a small increase in soft tissue hydration (interstitial gel fluid). Body composition changes did not significantly differ among groups of previous contraceptive methods. Arterial blood pressure did not significantly change over time.</p> <p>Conclusion</p> <p>After 6 months of treatment with the ethinylestradiol/norelgestromin contraceptive patch we found a minimal, clinically not relevant, increase in body weight less than 1 kg that could be attributed to an adaptive interstitial gel hydration. This fluctuation is physiological as confirmed by the lack of any effect on blood pressure. This could be useful in increasing women's choice, acceptability and compliance of the ethinylestradiol/norelgestromin contraceptive patch.</p
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia
The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and encompass a long accrual of progressive biological (preclinical) and then clinical (prodromal) changes, antedating the onset of dementia. The heterogeneity of clinical presentations and the different neuropathological phenotypes have prevented a prior clear description of either preclinical or prodromal FTD. Recent advances in therapeutic approaches, at least in monogenic disease, demand a proper definition of these predementia stages. It has become clear that a consensus lexicon is needed to comprehensively describe the stages that anticipate dementia. The goal of the present work is to review existing literature on the preclinical and prodromal phases of FTD, providing recommendations to address the unmet questions, therefore laying out a strategy for operationalizing and better characterizing these presymptomatic disease stages
Ventricular volume expansion in presymptomatic genetic frontotemporal dementia
OBJECTIVE: To characterize the time course of ventricular volume expansion in genetic frontotemporal dementia (FTD) and identify the onset time and rates of ventricular expansion in presymptomatic FTD mutation carriers. METHODS: Participants included patients with a mutation in MAPT, PGRN, or C9orf72, or first-degree relatives of mutation carriers from the GENFI study with MRI scans at study baseline and at 1 year follow-up. Ventricular volumes were obtained from MRI scans using FreeSurfer, with manual editing of segmentation and comparison to fully automated segmentation to establish reliability. Linear mixed models were used to identify differences in ventricular volume and in expansion rates as a function of time to expected disease onset between presymptomatic carriers and noncarriers. RESULTS: A total of 123 participants met the inclusion criteria and were included in the analysis (18 symptomatic carriers, 46 presymptomatic mutation carriers, and 56 noncarriers). Ventricular volume differences were observed 4 years prior to symptom disease onset for presymptomatic carriers compared to noncarriers. Annualized rates of ventricular volume expansion were greater in presymptomatic carriers relative to noncarriers. Importantly, time-intensive manually edited and fully automated ventricular volume resulted in similar findings. CONCLUSIONS: Ventricular volume differences are detectable in presymptomatic genetic FTD. Concordance of results from time-intensive manual editing and fully automatic segmentation approaches support its value as a measure of disease onset and progression in future studies in both presymptomatic and symptomatic genetic FTD
- …